Literature DB >> 32125269

Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020.

Jiaye Liu, Xuejiao Liao, Shen Qian, Jing Yuan, Fuxiang Wang, Yingxia Liu, Zhaoqin Wang, Fu-Sheng Wang, Lei Liu, Zheng Zhang.   

Abstract

Since early January 2020, after the outbreak of coronavirus infection in Wuhan, China, ≈365 confirmed cases have been reported in Shenzhen, China. The mode of community and intrafamily transmission is threatening residents in Shenzhen. Strategies to strengthen prevention and interruption of these transmissions should be urgently addressed.

Entities:  

Keywords:  2019 novel coronavirus; COVID-19; China; SARS-CoV-2; Shenzhen; community transmission; coronavirus; epidemiologic; respiratory infections; severe respiratory syndrome coronavirus 2; viruses

Mesh:

Year:  2020        PMID: 32125269      PMCID: PMC7258448          DOI: 10.3201/eid2606.200239

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


In December 2019, an outbreak of a novel coronavirus infection (COVID-19), occurred in Wuhan, China (). Although China launched an emergency response early in the outbreak, the infection rapidly spread to metropolitan areas in China and around the world. The growing number of cases suggests that the epidemic has continued to spread. Several research articles have reported the epidemiologic characteristics of the outbreak in Wuhan and Hubei Province (–); however, to our knowledge, an analysis of the epidemic in metropolis areas around Wuhan has not yet been reported. To predict the epidemic trend and guide control measures, especially in similar metropolitan areas, outbreak investigations are needed. Shenzhen, a modern and international metropolitan city, is located in southern China (Appendix Figure 1) and has a population of 13 million persons, among which >1 million are from Hubei Province and >70,000 from Wuhan. After the first cluster of COVID-19 cases was confirmed in Shenzhen in early January 2020 (), other cases spread within the city, involving all districts. To summarize the epidemiologic characteristics and provide updated information to aid in the development of control measures, we analyzed data for the first 365 laboratory-confirmed cases of COVID-19 in Shenzhen.

The Cases

In early January 2020, a total of 24 days after the index COVID-19 case occurred in Wuhan, a familial cluster of COVID-19 case-patients who had traveled to Wuhan from December 29, 2019, through January 4, 2020, was identified in Shenzhen (). Subsequently, more cases in the city were reported. Analysis of spatiotemporal dynamics indicated that the infection spread more broadly throughout the city (Figure; Appendix Figure 2). Since January 17, infections increased substantially, peaking January 22–30. The decline since January 30 is probably the result of underascertainment of cases with recent onset and delayed identification or reporting (Figure).
Figure

Onset of illness timeline for the first 365 confirmed COVID-19 case-patients in Shenzhen, China. The decline in incidence after January 30, 2020, probably resulted from delays in diagnosis and laboratory confirmation. All cases in this curve were confirmed. Hospital-based surveillance began January 8, 2020, for patients with suspected cases, defined by having a history of travel to Wuhan within the past 14 days, fever, and radiographic evidence of viral pneumonitis. PCR confirmation began January 13, 2020, and subsequently expanded the criteria for patients with suspected cases, defined by having typical clinical manifestations of COVID-19 and excluding infection caused by type A and B influenza and respiratory syncytial virus, regardless of travel history. NCIP, novel coronavirus–infected pneumonia (now called COVID-19).

Onset of illness timeline for the first 365 confirmed COVID-19 case-patients in Shenzhen, China. The decline in incidence after January 30, 2020, probably resulted from delays in diagnosis and laboratory confirmation. All cases in this curve were confirmed. Hospital-based surveillance began January 8, 2020, for patients with suspected cases, defined by having a history of travel to Wuhan within the past 14 days, fever, and radiographic evidence of viral pneumonitis. PCR confirmation began January 13, 2020, and subsequently expanded the criteria for patients with suspected cases, defined by having typical clinical manifestations of COVID-19 and excluding infection caused by type A and B influenza and respiratory syncytial virus, regardless of travel history. NCIP, novel coronavirus–infected pneumonia (now called COVID-19). Evaluation of the potential risk for local transmission will help determine whether patients with newly reported cases had definite exposure, defined by either having had definite contact with confirmed case-patients or having traveled to Wuhan or other cities in Hubei, or both, over the past 14 days. Overall, most (91%) cases that we report had definite exposure. On January 14, the first infected case-patient without definite exposure was reported in Shenzhen. Since January 20, growing numbers of cases without definite exposure were observed. Compared with the proportion before January 24, the proportion of case-patients without definite exposure was much higher from January 25 through February 5 (11% vs. 6%; p<0.001) and increased to 36% (12/33) on both January 31 and February 5. These data suggest an increasing risk for community transmission (Table 1; Figure).
Table 1

Characteristics of patients with severe acute respiratory syndrome coronavirus 2 infection in Shenzhen, China, as of February 5, 2020

CharacteristicBefore Jan 24, n = 166Jan 25–Feb 5, n = 199p value
Median age (range), y
52 (1–81)
40 (1–86)
<0.001
Age group, no. (%)<0.001
<154 (2)26 (13)
15–3430 (18)44 (22)
35–5460 (36)70 (35)
>55
72 (43)
59 (30)

Patient sex, no. (%)0.428
M 79 (48)103 (52)
F
87 (52)
96 (48)

Exposure history, no. (%)<0.001
Contact with confirmed case-patients71 (43)109 (55)
Wuhan78 (47)42 (21)
Cities other than Wuhan in Hubei Province7 (4)26 (13)
No definite exposure
10 (6)
22 (11)

First visited designated hospital, no. (%)22 (13)29 (15)0.717
Days between illness onset and visiting hospital, median (range)3 (0–15)1 (0–9)<0.001
We analyzed the clinical and epidemiologic characteristics of 365 persons with laboratory-confirmed cases in Shenzhen. The median case-patient age was 46 (range 1–86) years; 182 (50%) case-patients were male. To investigate the shift of the epidemic, we compared characteristics of case-patients during 2 periods: before January 24 (the Chinese Spring Festival) and after January 25 (until February 5). Because of delays between infection to illness onset or illness onset to confirmation, the following comparisons between the 2 periods might be biased because of misclassification. We found a sharply increasing proportion of infected children (from 2% before January 24 to 13% for January 25–February 5; p<0.001), implying that increased exposure for children and intrafamily transmission might contribute substantially to the epidemic. Although substantially higher after January 25, 2020, the proportion of infected children in our study before January 24, 2020, was similar to the proportions reported by Li et al () (0/425, based on cases as of January 22, 2020) and Guan et al. (W.J. Guan et al., unpub. data, https://doi.org/10.1101/2020.02.06.20020974) (9/1,099 as of January 29, 2020). The possible reasons for the discrepancy after January 25 might be the low proportion of children exposed early in the outbreak; early detection for children who had had close contact with persons with diagnosed or suspected cases after strict control measures were conducted comprehensively; and difficult identification of the relatively milder clinical signs and symptoms in young patients than in infected adults (), especially in the setting of limited resources in the early phase of the outbreak in Wuhan. We explored the incubation periods for 58 case-patients with definite exposure and detailed investigation information. The estimated mean incubation periods were 6.1 (range 1–16) days among 33 case-patients who had had close contact with symptomatic confirmed case-patients and 6.0 (range 1–15) days among 25 case-patients who had traveled to Wuhan and stayed <1 day over the previous 3 weeks (Table 2; Appendix Table 1). Estimated incubation periods were consistent with those previously reported (). We analyzed the characteristics of 74 clusters involving 183 cases (2–6 cases/cluster). Among 12 clusters of single intracluster transmission cases, 15 case-patients were infected within 5.5 days of the mean interval between illness onset of the infector and illness onset of the infectee. Among 56 clusters of single co-exposure cases, the mean interval of symptom onset between the primary and second case-patient within a cluster was 3.1 days, and the mean interval of symptom onset between the primary and last case-patient within a cluster was 3.6 days (Appendix Table 2).
Table 2

Estimated incubation periods for severe acute respiratory syndrome coronavirus 2, stratified by exposure classification, Shenzhen, China, as of February 5, 2020

ExposureNo. patientsMean, dMedian, dInterquartile range, dRange, d
Contact with confirmed symptomatic case-patient336.153–81–16
Traveled to Wuhan and stayed <1 day
25
6.0
5
3–8
1–15
Total586.053–81–16
With continuous implementation of strict control measures, we observed a shortened span (median days declining from 3 to 1; p<0.001) between illness onset and hospital visits for case-patients (Table 1). This finding may result from strict infection control management (e.g., early screening for suspected cases, monitoring for close-contact persons, and improved health consciousness of the general population). To control the infection, confirmed case-patients should be separated and managed centrally; thus, the government has designated special hospitals to admit patients with suspected or confirmed cases. Nevertheless, as of February 5, to our knowledge, 1 case of a healthcare worker having been infected has been reported; an emergency nurse from a nondesignated hospital became ill on January 26, 2020, a total of 8 days after having been in close contact with a confirmed case-patient in the outpatient setting. We found that only 13%–15% of patients with confirmed cases went to the designated hospital first during the epidemic period. This finding means that a substantial number of case-patients visited >1 nondesignated hospital before they were admitted to the designated hospital, which increases the risk for nosocomial infection.

Conclusions

Essential for the control of this extremely contagious disease are close monitoring and timely reporting of the epidemic to the public as well as evaluation of the current control strategy. On the basis of this epidemiologic analysis, we found that COVID-19 has become endemic to Shenzhen, China. We suspect that community transmission and intrafamily transmission have potentially become the new transmission modes in the city. Also, nosocomial infection and transmission might pose a potential risk for COVID-19 control. To control this outbreak in Shenzhen, maintaining basic and essential strategies is crucial. Early screening, diagnosis, isolation, and treatment are necessary to prevent further spread (). Throughout the city, management of persons in close contact with persons with diagnosed and suspected cases, restriction of public activity, and use of personal protection measures should be continued. Strengthening effective and efficient measures, including but not limited to personal protection within families and communities with a high risk for exposure, will prevent and interrupt community and intrafamily transmission. To prevent nosocomial infection and transmission, a designated hospital should be the first choice for persons who had close contact with confirmed case-patients or who themselves have clinical signs indicative of COVID-19.

Appendix

Detailed information for COVID-19 case-patients with regard to incubation period, clusters, and spatiotemporal dynamics, Shenzhen, China.
  5 in total

Review 1.  Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus.

Authors:  Zhi-Min Chen; Jun-Fen Fu; Qiang Shu; Ying-Hu Chen; Chun-Zhen Hua; Fu-Bang Li; Ru Lin; Lan-Fang Tang; Tian-Lin Wang; Wei Wang; Ying-Shuo Wang; Wei-Ze Xu; Zi-Hao Yang; Sheng Ye; Tian-Ming Yuan; Chen-Mei Zhang; Yuan-Yuan Zhang
Journal:  World J Pediatr       Date:  2020-02-05       Impact factor: 2.764

2.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

3.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

4.  What to do next to control the 2019-nCoV epidemic?

Authors:  Fu-Sheng Wang; Chao Zhang
Journal:  Lancet       Date:  2020-02-08       Impact factor: 79.321

5.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

  5 in total
  185 in total

1.  Shall Universities at the UAE Continue Distance Learning after the COVID-19 Pandemic? Revealing Students' Perspective.

Authors:  Nasser A Saif Almuraqab
Journal:  SSRN       Date:  2020-06-08

2.  Genomic Analysis of Early SARS-CoV-2 Variants Introduced in Mexico.

Authors:  Blanca Taboada; Joel Armando Vazquez-Perez; José Esteban Muñoz-Medina; Pilar Ramos-Cervantes; Marina Escalera-Zamudio; Celia Boukadida; Alejandro Sanchez-Flores; Pavel Isa; Edgar Mendieta-Condado; José A Martínez-Orozco; Eduardo Becerril-Vargas; Jorge Salas-Hernández; Ricardo Grande; Carolina González-Torres; Francisco Javier Gaytán-Cervantes; Gloria Vazquez; Francisco Pulido; Adnan Araiza-Rodríguez; Fabiola Garcés-Ayala; Cesar Raúl González-Bonilla; Concepción Grajales-Muñiz; Víctor Hugo Borja-Aburto; Gisela Barrera-Badillo; Susana López; Lucía Hernández-Rivas; Rogelio Perez-Padilla; Irma López-Martínez; Santiago Ávila-Ríos; Guillermo Ruiz-Palacios; José Ernesto Ramírez-González; Carlos F Arias
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

3.  Early centralized isolation strategy for all confirmed cases of COVID-19 remains a core intervention to disrupt the pandemic spreading significantly.

Authors:  Nguyen Hai Nam; Phan Thi My Tien; Le Van Truong; Toka Aziz El-Ramly; Pham Gia Anh; Nguyen Thi Hien; El Marabea Mahmoud; Mennatullah Mohamed Eltaras; Sarah Abd Elaziz Khader; Mohammed Salah Desokey; Ramy Magdy Gayed; Shamael Thabit Mohammed Alhady; Bao-Tran Do Le; Do Phuc Nhu Nguyen; Ranjit Tiwari; Mohammed Eldoadoa; Britney Howard; Tran Thanh Trung; Nguyen Tien Huy
Journal:  PLoS One       Date:  2021-07-15       Impact factor: 3.240

4.  Prevalence of COVID-19 in health professionals and occupational psychosocial risks.

Authors:  Mafalda Sousa-Uva; Antonio Sousa-Uva; Florentino Serranheira
Journal:  Rev Bras Med Trab       Date:  2021-04-30

5.  Guidance for nebulization during the COVID-19 pandemic.

Authors:  Rajesh Swarnakar; Neeraj M Gupta; Indranil Halder; Gopi C Khilnani
Journal:  Lung India       Date:  2021-03

6.  Discrete and continuum models of COVID-19 virus, formal solutions, stability and comparison with real data.

Authors:  Hamdy I Abdel-Gawad; Ahmed H Abdel-Gawad
Journal:  Math Comput Simul       Date:  2021-05-14       Impact factor: 2.463

7.  Risk perceptions and attitudinal responses to COVID-19 pandemic: an online survey in Ethiopia.

Authors:  Zewdie Birhanu; Argaw Ambelu; Diriba Fufa; Mohammed Mecha; Ahmed Zeynudin; Jemal Abafita; Ashenafi Belay; Feleke Doyore; Lemessa Oljira; Endale Bacha; Jilcha Feyisa; Zinabu Hadis; Ketema Ayele; Yohannes Addisu; Birhanu Gutu; Demu Tesfaye; Temesgen Tilahun; Gudeta Imana; Tadele Tolosa; Seblework Mekonen; Yimenu Yitayih; Nega Jibat; Mathewos Moges; Ayinengida Adamu; Abraham Teym; Adamu Kenea; Taffere Addis; Akalework Mengesha; Yohannes Kebede
Journal:  BMC Public Health       Date:  2021-05-25       Impact factor: 3.295

8.  An enhanced method for nucleic acid detection with CRISPR-Cas12a using phosphorothioate modified primers and optimized gold-nanopaticle strip.

Authors:  Jiaojiao Gong; Lijuan Kan; Xiuming Zhang; Ying He; Jiaqiang Pan; Liping Zhao; Qianyun Li; Menghao Liu; Jie Tian; Sili Lin; Zhouyu Lu; Liang Xue; Chaojun Wang; Guanghui Tang
Journal:  Bioact Mater       Date:  2021-05-15

9.  A Simple Electrostatic Precipitator for Trapping Virus Particles Spread via Droplet Transmission.

Authors:  Koji Kakutani; Yoshinori Matsuda; Teruo Nonomura; Yoshihiro Takikawa; Takeshi Takami; Hideyoshi Toyoda
Journal:  Int J Environ Res Public Health       Date:  2021-05-06       Impact factor: 3.390

10.  SARS-CoV-2 infection paralyzes cytotoxic and metabolic functions of the immune cells.

Authors:  Yogesh Singh; Christoph Trautwein; Rolf Fendel; Naomi Krickeberg; Georgy Berezhnoy; Rosi Bissinger; Stephan Ossowski; Madhuri S Salker; Nicolas Casadei; Olaf Riess
Journal:  Heliyon       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.